Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 7, 2026, 7:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Small Cell Lung Cancer Limited Stage Clear all
Recruiting Phase 1 Interventional

Safety Trial of Antimicrobial Therapy and Precision Radiation Therapy in Patients With Oligoprogressive Non-small Cell Lung Cancer

NCT03546829
View directory record Official record
Conditions
Early Stage Non-Small Cell Lung Cancer
Interventions
Vancomycin, Precision hypofractionated radiation
Drug · Radiation
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Jun 7, 2026, 7:47 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)

NCT04585477
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Stage I, Non-small Cell Lung Cancer Stage II, Non-small Cell Lung Cancer Stage III
Interventions
AVENIO ctDNA Surveillance Kit, Durvalumab, Durvalumab (Imfinzi) alone or in combination with platinum-based chemotherapy
Device · Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Jun 7, 2026, 7:47 AM EDT
Recruiting Phase 1 Interventional

Honokiol in Early-Stage Resectable Non-Small Cell Lung Cancer

NCT06566443
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Honokiol
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Jun 7, 2026, 7:47 AM EDT
Recruiting No phase listed Observational

Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform

NCT06349642
View directory record Official record
Conditions
Early Stage Triple-Negative Breast Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Cervical Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Endometrial Carcinoma, Metastatic Esophageal Carcinoma, Metastatic Liver Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Skin Neoplasm, Metastatic Malignant Solid Neoplasm, Resectable Lung Non-Small Cell Carcinoma, Early Stage Lung Non-Small Cell Carcinoma, Resectable Malignant Solid Neoplasm, Resectable Triple-Negative Breast Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Cervical Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8, Recurrent Cervical Carcinoma, Recurrent Colorectal Carcinoma, Recurrent Endometrial Carcinoma, Recurrent Esophageal Carcinoma, Recurrent Liver Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Recurrent Malignant Skin Neoplasm, Recurrent Malignant Solid Neoplasm
Interventions
Biospecimen Collection, Tissue Collection
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
324 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
3
States / cities
Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Jun 7, 2026, 7:47 AM EDT
Completed Phase 3 Interventional

Vaccination Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer

NCT00003279
View directory record Official record
Conditions
Lung Cancer
Interventions
BCG vaccine, monoclonal antibody BEC2
Biological
Lead sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Network
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
34
States / cities
Birmingham, Alabama • Scottsdale, Arizona • La Jolla, California + 29 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2012 · Synced Jun 7, 2026, 7:47 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer

NCT04735068
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, KRAS Mutation-Related Tumors
Interventions
Binimetinib Pill, Hydroxychloroquine Pill
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 31, 2025 · Synced Jun 7, 2026, 7:47 AM EDT
Completed Phase 2 Interventional Results available

Pilot Study of Preoperative Tarceva (Erlotinib) for Stages I/II Non-Small Cell Lung Cancer

NCT00385996
View directory record Official record
Conditions
Carcinoma, Non-small Cell Lung
Interventions
Tarceva (Erlotinib)
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 85 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 27, 2018 · Synced Jun 7, 2026, 7:47 AM EDT
Completed Phase 2 Interventional

VNP40101M in Treating Patients With Relapsed or Refractory Locally Advanced or Metastatic Small Cell Lung Cancer

NCT00282022
View directory record Official record
Conditions
Lung Cancer
Interventions
laromustine
Drug
Lead sponsor
Vion Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
9
States / cities
Los Angeles, California • New Haven, Connecticut • West Haven, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2013 · Synced Jun 7, 2026, 7:47 AM EDT
Completed Phase 2 Interventional Results available

Irinotecan and Carboplatin in Treating Patients With Metastatic or Recurrent Small Cell Lung Cancer

NCT00387660
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, irinotecan
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jan 9, 2018 · Synced Jun 7, 2026, 7:47 AM EDT
Terminated Phase 2 Interventional Results available

Rebeccamycin Analog as Second-Line Therapy in Treating Patients With Limited-Stage or Extensive-Stage Small Cell Lung Cancer That Relapsed After Previous First-Line Chemotherapy

NCT00084487
View directory record Official record
Conditions
Extensive Stage Small Cell Lung Cancer, Limited Stage Small Cell Lung Cancer, Recurrent Small Cell Lung Cancer
Interventions
becatecarin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 22, 2014 · Synced Jun 7, 2026, 7:47 AM EDT
Completed Not applicable Interventional

SBRT (Stereotactic Body Radiation Therapy) vs. Surgery in High Risk Patients With Early Stage Lung Cancer

NCT02562027
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell-Lung, Non-Small Cell Lung Cancer, Nonsmall Cell Lung Cancer
Interventions
European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire LC-13, Modified Medical Research Council, EQ-5D, Center for Epidemiological Studies Depression Scale, Medical Outcomes Study Social Support Survey
Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 7, 2021 · Synced Jun 7, 2026, 7:47 AM EDT
Completed Phase 2 Interventional Results available

Dasatinib in Treating Patients With Relapsed Small Cell Lung Cancer

NCT00470054
View directory record Official record
Conditions
Extensive Stage Small Cell Lung Cancer, Limited Stage Small Cell Lung Cancer, Recurrent Small Cell Lung Cancer
Interventions
dasatinib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 4, 2015 · Synced Jun 7, 2026, 7:47 AM EDT
Completed Phase 1 Interventional

Photodynamic Therapy With HPPH in Treating Patients With Non-Small Cell Lung Cancer

NCT00025571
View directory record Official record
Conditions
Lung Cancer
Interventions
HPPH
Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Mar 6, 2011 · Synced Jun 7, 2026, 7:47 AM EDT
Completed Phase 1 Interventional

Neoadjuvant Chemoradiotherapy Followed By Surgery in Treating Patients With Limited-Stage Small Cell Lung Cancer

NCT00062322
View directory record Official record
Conditions
Lung Cancer
Interventions
cisplatin, irinotecan hydrochloride, conventional surgery, neoadjuvant therapy, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 11, 2010 · Synced Jun 7, 2026, 7:47 AM EDT
Completed Phase 1 Interventional

S0004: Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Limited-stage Small Cell Lung Cancer

NCT00006487
View directory record Official record
Conditions
Lung Cancer
Interventions
cisplatin, etoposide, tirapazamine, radiation therapy
Drug · Radiation
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
87
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 56 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2012 · Synced Jun 7, 2026, 7:47 AM EDT
Completed No phase listed Observational

Study of Symptoms Caused by Cancer and Cancer Therapy in Patients With Invasive Breast, Lung, Prostate, or Colorectal Cancer

NCT00303914
View directory record Official record
Conditions
Breast Cancer, Cognitive/Functional Effects, Colorectal Cancer, Lung Cancer, Pain, Prostate Cancer, Psychosocial Effects of Cancer and Its Treatment
Interventions
assessment of therapy complications, cognitive assessment, psychosocial assessment and care
Procedure
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 120 Years
Enrollment
2,310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
32
States / cities
Chicago, Illinois • Evanston, Illinois • Elkhart, Indiana + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2023 · Synced Jun 7, 2026, 7:47 AM EDT
Recruiting Phase 2 Interventional

Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

NCT05061550
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Durvalumab, Oleclumab, Monalizumab, Dato-DXd, AZD0171, Carboplatin, Cisplatin, Pemetrexed/Cisplatin, Pemetrexed/Carboplatin, Carboplatin/Paclitaxel, Volrustomig, Rilvegostomig
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 95 Years
Enrollment
630 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
24
States / cities
Little Rock, Arkansas • Los Angeles, California • Oakland, California + 18 more
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jun 7, 2026, 7:47 AM EDT
Withdrawn Phase 2 Interventional

Pembrolizumab With or Without Chemotherapy Before Surgery in Treating Patients With Stage I-IIIA Non-Small Cell Lung Cancer

NCT04061590
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage IA1 Lung Cancer AJCC v8, Stage IA2 Lung Cancer AJCC v8, Stage IA3 Lung Cancer AJCC v8, Stage IB Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8
Interventions
Cisplatin, Pembrolizumab, Pemetrexed, Pemetrexed Disodium, Therapeutic Conventional Surgery
Drug · Biological · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 3, 2022 · Synced Jun 7, 2026, 7:47 AM EDT
Terminated Phase 2 Interventional

S0122: Combination Chemotherapy, Radiation Therapy, and Vaccine Therapy in Limited-Stage Small Cell Lung Cancer

NCT00045617
View directory record Official record
Conditions
Lung Cancer
Interventions
monoclonal antibody 11D10 anti-idiotype vaccine, monoclonal antibody GD2 anti-idiotype vaccine, cisplatin, etoposide, radiation therapy
Biological · Drug · Radiation
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003
U.S. locations
99
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2012 · Synced Jun 7, 2026, 7:47 AM EDT
Terminated Phase 2 Interventional Results available

Phase II Study Evaluating The Safety And Response To Neoadjuvant Dasatinib In Early Stage Non-Small Cell Lung Cancer

NCT00564876
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Dasatinib
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 22, 2015 · Synced Jun 7, 2026, 7:47 AM EDT
Not listed Not applicable Interventional

Stereotactic Body Radiation Therapy for Un-biopsied Early- Stage Non Small Cell Lung Cancer

NCT02950337
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Group 1: Peripherally Located Tumors, Group 2: Peripherally Located Chest Wall Adjacent Tumors, Group 3: Centrally Located Tumors
Radiation
Lead sponsor
Loyola University
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
2
States / cities
Hines, Illinois • Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 20, 2023 · Synced Jun 7, 2026, 7:47 AM EDT
Completed Phase 2 Interventional

Amifostine in Treating Peripheral Neuropathy Caused by Paclitaxel in Patients With Solid Tumors

NCT00078845
View directory record Official record
Conditions
Breast Cancer, Lung Cancer, Neurotoxicity, Ovarian Cancer, Prostate Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
Amifostine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
15
States / cities
Decatur, Illinois • Urbana, Illinois • Wichita, Kansas + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2012 · Synced Jun 7, 2026, 7:47 AM EDT
Terminated Not applicable Interventional Results available

Evaluation of Apricoxib (Selective Cyclooxygenase 2 Inhibition) in Modulating T Regulatory Cells of Patients With Early Stage Non-small Cell Lung Cancer

NCT01532362
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Apricoxib
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 21, 2020 · Synced Jun 7, 2026, 7:47 AM EDT
Completed Not applicable Interventional

Printed Education Materials in Patients Who Are Finishing Treatment for Stage I, Stage II, or Stage IIIA Breast Cancer, Colorectal Cancer, Prostate Cancer, or Chest Cancer

NCT00372840
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Lung Cancer, Malignant Mesothelioma, Prostate Cancer, Psychosocial Effects of Cancer and Its Treatment, Thymoma and Thymic Carcinoma
Interventions
educational intervention, psychosocial assessment and care, quality-of-life assessment
Other · Procedure
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 1, 2020 · Synced Jun 7, 2026, 7:47 AM EDT